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Hh-Gli signaling pathway is one of the major and highly conserved pathways regulating em-
bryogenesis and organ development. Its aberrant functioning is associated with malformations
and cancer. Major proteins involved in the pathway are Hh, Ptch, Smo, and Gli1. Recent dis-
coveries showed that the pathway is involved in many common and lethal tumors, such as breast,
lung, prostate and digestive tract cancer. In these cases, tumor growth appears to require ab-
normal Hh stimulation from the surrounding cells, which causes a strong intracellular response
of the pathway. Extensive involvement of the Hh-Gli pathway in tumor development has pro-
moted it into an important target for cancer therapy, by discovery of a small molecule, cyclo-
pamine, which was shown to block Smo. Successful tumor growth inhibition was accomplish-
ed both in cell cultures and on animal models. Current research includes analogous molecules,
and alternative strategies of intervention on the other elements of the Hh-Gli pathway.
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INTRODUCTION
The Hh-Gli signaling pathway, also known as Hh-Ptc or
Hh/Ptc/Smo, is highly conserved through evolution, and
plays a critical role in early development of embryos and
organs, both in insects and in mammals. Disturbances in
the functioning of the Hh-Gli pathway cause various de-
velopmental deformities, and are involved in canceroge-
nesis. The distinct role of the Hh-Gli pathway in tumors
linked to Gorlin syndrome (also known as NBCCS, Ne-
void Basal Cell Carcinoma Syndrome) has been known
for more than ten years, but its involvement in more com-
mon and deadly tumors such as breast, lung, prostate and
digestive tract cancer became apparent only in last several
years. Recently the Hh-Gli signaling pathway has been
associated with two more human cancers, glioma,1 and
melanomas.2
The Hh-Gli pathway in adult organism is inactive in
most cell types. It is normally activated only during de-
velopment of particular organs. In such instances, a secret-
ed protein Hh (Hedgehog) binds to a transmembrane pro-
tein Ptc (Patched), which releases its repression of Smo
(Smoothened, also a transmembrane protein). This trig-
gers a signaling cascade within the cell, causing expres-
sion of target genes. Among those genes is the PTC it-
self, which limits and finally blocks the pathway activity
(Figure 1).
The Hh-Gli signaling is essential for proliferation of
neural precursor populations in the developing central ner-
vous system (CNS). Hh-Gli signaling modulates normal
dorsal brain growth,3 regulates number of embryonic and
postnatal neocortical cells with stem cell properties,4 and
is required to maintain progenitor cells in the postnatal
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telencephalon.5 Hh-Gli signaling represents a large set of
gene regulation networks that control stem cell fate through-
out development and into adulthood.6
Many details of complex interactions within the Hh-
Gli pathway are still poorly understood, in particular in
case of its abnormal activation involved in malignant pro-
cesses. Nonetheless, successful inhibitions of the Hh-Gli
pathway have been accomplished in some tumors in la-
boratory conditions.
DETAILS OF THE PATHWAY MECHANISM
In humans, three different homologues of secreted ligand
hedgehog (Hh) are known: Sonic Hedgehog (Shh), Indian
Hedgehog (Ihh) and Desert Hedgehog (Dhh), all of them
are tissue specific. Their activity is dependent on two
posttranslational modifications of the protein, one is the
binding of cholesterol to the C-terminus, of the N-termi-
nal fragment of the newly synthesized Hh protein (Hh-N),
and the other is palmitoylation of one cystein residue in
the protein.
Any of these isoforms binds to the receptor Patched
(Ptch), which is a 12-pass transmembrane protein. The
Patched gene (PTCH), which belongs to a segment pola-
rity family, has two human homologues; after discovery
of PTCH2, the PTCH gene is sometimes referred to as
PTCH1.
Hh binding causes Ptch to relieve its repression of
Smoothened (Smo). This is achieved catalytically via a
small molecule, but the identity of this small regulating
molecule is still unknown. Smo is a seven-pass transmem-
brane protein similar to G-protein coupled receptors, and
appears to have no other homologues.7
Smo activates downstream pathway components by
phosphorylation. These components include Fused (Fu),
Suppressor of Fused (Su(Fu)), Costal2 (Cos2) and Gli
proteins.8 Cos2 is a kinesin-like protein which in its low
phosphorylated state keeps this complex bound to micro-
tubules. When Smo is phosphorylated by a G-protein
coupled receptor kinase 2 (Grk2), it associates with Cos2;
Fu is phosphorylated and this leads to release of Gli. Fu
can also bind directly to Smo and to Su(Fu). Su(Fu) acts as
a negative regulator of the pathway.9,10
The zinc finger transcription factors Gli1, Gli2 and
Gli3 mediate Hh signaling during development, but their
expression is also found in several human tumors, includ-
ing basal cell carcinomas, medulloblastomas and sarco-
mas. Many of Gli1 targets are associated with cell proli-
feration, indicating that this oncogene induces cell trans-
formation through multiple downstream pathways.11 There
are three GLI transcription factors in vertebrates: Gli1 ap-
pears to act as a transcriptional activator and is univer-
sally induced in Hh-responding cells, whereas Gli2 and
Gli3 can act as activators or repressors of transcription
depending on the cellular context. In particular, Gli1 in-
duces the expression of individual PTCH transcripts in a
cell type-specific manner, by direct interaction of Gli1 and
the PTCH promoter region, where Gli1-binding sites have
been found.12 Therefore, sequence alterations or mere
epigenetic events (such as methylation) in the promoter
region can impair Ptch regulatory function.13
Other target genes important for the oncogenic func-
tion of the Hh-Gli pathway may be those involved in
controlling cell proliferation (cyclin D, cyclin E, Myc,
b-catenin and the components of the epidermal growth
factor pathway) and in angiogenesis (components of the
platelet-derived growth factor and of the vascular-epi-
thelial growth factor pathway).14,15
Also, a number of additional genes have recently been
reported to be associated with the pathway. Among them,
Hippi is an adapter protein that mediates pro-apoptotic
signaling to the extrinsic cell death pathway. In the ab-
sence of Hippi Hh-Gli pathway is downregulated and er-
rors occur during embryonic development: defective left-
right axis patterning and defects in neural tube develop-
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Figure 1. A simplified diagram of the Hh-Gli pathway: (a) in the absence of Hh, Ptch represses Smo and the pathway is inactive, Cos2 keeps
the Hedgehog signaling complex tethered to the microtubules, Gli1 is bound in the cytoplasm and there is no transcription of target genes;
(b) in the presence of Hh, Hh binds to Ptch, Smo is relieved and activates a cascade that leads to trascription of the pathway target genes.
ment.16 Numb is a developmental protein that has criti-
cal roles in cell-fate determination and differentiation. It
functions as an adapter protein during ubiquitination. Gli1
is targeted by Numb for Itch-dependent ubiquitination,
which suppresses hedgehog signal, arrests growth and
promotes cell differentitation.17
DEVELOPMENTAL ROLE CONSERVED
THROUGH EVOLUTION
Hh-Gli signaling pathway was first discovered in fruit fly
(Drosophila melanogaster), and the proteins were named
after phenotypical characteristics their deletion induced
in fruit flies. Hedgehog was named this way because the
fruit fly larva with mutated HH gene showed unusual
ridges on its back similar to hedgehog spines. Patched
and Smoothened were named after the phenotypical cha-
racteristics of the fruit fly wings.18 Only Gli was named
after glioblastoma, because amplification of this gene
was found in glioblastoma patients.
The entire pathway is highly conserved through
evolution, from nematodes to vertebrates, and plays a
major role in embryonic development. Nematodes seem
to lack many components of the pathway, including Hh
itself, though there are two Ptc related genes. There are
also some differences between mammals, zebrafish and
Drosophila melanogaster.18
Recently, it has been shown that Shh gene experienc-
ed intensified molecular evolution in primates, and ac-
cording to the nature of the changes it is postulated that
these changes enable more complex post-translational
modifications in primates and lineage leading to hu-
mans.19
Hh-Gli signaling pathway is one of the major path-
ways regulating embryogenesis. It is involved in various
tissues in various stages of development, and acts as a
mitogenic, morphogenic or differentiation factor. Shh
controls the development of the neural tube, limbs,
digestive system, lungs, hair follicles, eyes and left/right
side symmetry. Ihh is expressed in the digestive system
and cartilage, and regulates bone development. Dhh is
involved in Sertoli cells in the testes, where it is involv-
ed in differentiation of germline cells,20 as well as se-
creted from Schwann cells where it regulates the forma-
tion of surrounding tissues.21
Malfunctioning or aberrant activation of the pathway
in the wrong tissue or in the wrong stage of development
leads to malformations and disease, and complete lack
of Shh or Ptch genes terminates the embryo early in de-
velopment.
ROLE IN HUMAN DISEASES
There are two hypothetical models of abnormal Hh-Gli
pathway activation that can be distinguished in research
papers published on this subject in the last several years.
One model suggests constitutive activation of the path-
way within the cell, and does not require outside stimu-
lation by Hh signal. This model is associated with e.g.
basocellular carcinoma and ovarian fibromas. The other
model suggests abnormal Hh stimulation from the sur-
rounding cells, which causes a strong intracellular response
of the pathway. This model is recently associated with
more deadly tumors such as lung and breast cancer.22,23
Hh-Gli pathway malfunctioning in humans was ini-
tially associated with a medical condition called Gorlin
syndrome. This syndrome is characterized by multiple
developmental anomalies, such as cleft lip or palate,
macrocephaly, pits on palms and soles, spina bifida; but
also with various tumors: basocellular carcinoma of the
skin (BCC), medulloblastoma, rhabdomyosarcoma, ova-
rian fibroma and dermoids, jaw cysts and meningioma.
Gorlin syndrome is caused by a germline mutation in
PTCH gene, whose haploinsufficiency leads to malfor-
mations, and a somatic mutation of the second allele leads
to tumor formation.
Many tumors associated with Gorlin syndrome can
also appear sporadically. In those cases the involvement
of the pathway has also been shown, proving the impor-
tance of this pathway not only in embryonic development
but also in the homeostasis of the adult organism.
Although this pathway was mostly associated with
benign tumors and tumors with low metastatic potential,
in recent years its role in various fatal tumors is becom-
ing more and more prominent. An increased activity of
GLI1, PTCH and HH genes has been detected in a series
of tumors not related to Gorlin syndrome (lung, breast,
prostate, pancreas etc.).22,23 It is suggested that, in these
tumors, the mechanism of Hh-Gli pathway activation is
dependent on the increased expression of HH gene and
ligand conformation (vital for a successful binding to Ptc).
According to some estimates, the pathway may be in-
volved in one third of all lethal tumors.
THERAPEUTIC POTENTIAL
Initial knowledge about possible antagonists of this path-
way came from studies of malformed sheep in California.
It has been noticed that sheep grazing on the hillsides often
gave birth to malformed lambs, mostly bearing cyclopia.
The main cause of this condition was a mountain lily,
Veratrum californicum, more specifically an alkaloid
compound extracted from it named cyclopamine (Figure
2). Cyclopamine was shown to block Smo and success-
ful tumor growth inhibition was accomplished both in
cell cultures and on animal models.24 Other similar natural
or synthetic alkaloids were found to inhibit the pathway.
So far, the research in inhibition of the Hh-Gli path-
way was mostly based on antagonizing Smo with cyclo-
pamine and its analogues (Table I); however, the question
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remains whether this will be applicable in vivo on human
tumors. Influencing Smo in the Hh-Gli signaling path-
way has the obvious advantage of not being dependent
on pathway activation with Hh. The drawback is the fact
that it leads to a general violent Hh-Gli pathway shut-
down and does not act on the cause of the abnormal acti-
vation of the pathway.
Alternative strategies of intervention on the other ele-
ments of the Hh-Gli pathway have only recently began
to be researched (the best results were achieved by
blocking Shh binding to Ptc with anti-Shh antibodies).35
In a model of ligand-dependent activation it might be best
act on the source – to suppress Hh gene expression or
impede protein conformation – and in the case of a li-
gand-independent model to boost Ptc gene expression or
continuously replace the protein.
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Figure 2. The cyclopamine molecule.
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SA@ETAK
Signalni put Hh-Gli i mogu}nosti primjene u terapiji raka
Sonja Levanat, Maja ^retnik i Vesna Musani
Signalni put Hh-Gli jedan je od najva`nijih i visoko o~uvanih puteva koji reguliraju embriogenezu i razvoj
organa. Njegovo se poreme}eno funkcioniranje povezuje s malformacijama i rakom. Glavni proteini uklju~eni
u taj put jesu: Hh, Ptch, Smo i Gli1. Poreme}eno fukcioniranje Hh-Gli puta kod ljudi u po~etku se povezivalo s
Gorlinovim sindromom, koji se pripisuje germinativnoj mutaciji jednog alela PTCH gena. Znatno su zanimlji-
vija nedavna otkri}a da je signalni put uklju~en u mnoge druge uobi~ajene i letalne tumore, kao {to su rak
dojke, plu}a, prostate i probavnog trakta. U tim se slu~ajevima ~ini da rast tumora zahtijeva abnormalnu Hh
stimulaciju iz okolnih stanica, koja uzrokuje sna`an me|ustani~ni odziv signalnog puta. Velika zastupljenost
signalnog puta Hh-Gli u razvoju tumora promovirala ga je u va`nu metu za terapiju raka, {to je bilo potpo-
mognuto otkri}em ciklopamina. Pokazalo se da ta mala molekula blokira Smo, ~ime je ostvarena uspje{na inhi-
bicija tumorskog rasta kako u stani~nim kulturama tako i na `ivotinjskim modelima. Dana{nja istra`ivanja uklju-
~uju ne samo analogne molekule nego i alternativne strategije djelovanja na druge elemente signalnog puta
Hh-Gli.
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